BMY
Price
$51.98
Change
+$1.03 (+2.02%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
103.74B
63 days until earnings call
Intraday BUY SELL Signals
RHHBY
Price
$48.92
Change
+$0.22 (+0.45%)
Updated
Dec 3 closing price
Capitalization
312.47B
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMY vs RHHBY

Header iconBMY vs RHHBY Comparison
Open Charts BMY vs RHHBYBanner chart's image
Bristol-Myers Squibb
Price$51.98
Change+$1.03 (+2.02%)
Volume$178.88K
Capitalization103.74B
Roche Holding
Price$48.92
Change+$0.22 (+0.45%)
Volume$1.4M
Capitalization312.47B
BMY vs RHHBY Comparison Chart in %
BMY
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BMY vs. RHHBY commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and RHHBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (BMY: $50.96 vs. RHHBY: $48.92)
Brand notoriety: BMY: Notable vs. RHHBY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 165% vs. RHHBY: 72%
Market capitalization -- BMY: $103.74B vs. RHHBY: $312.47B
BMY [@Pharmaceuticals: Major] is valued at $103.74B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $312.47B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $925.06B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $101.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • BMY’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, both BMY and RHHBY are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 5 TA indicator(s) are bullish while RHHBY’s TA Score has 5 bullish TA indicator(s).

  • BMY’s TA Score: 5 bullish, 5 bearish.
  • RHHBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than BMY.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а +3.47% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.06%. For the same industry, the average monthly price growth was +5.45%, and the average quarterly price growth was +13.09%.

Reported Earning Dates

BMY is expected to report earnings on Feb 05, 2026.

RHHBY is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-0.06% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($312B) has a higher market cap than BMY($104B). RHHBY has higher P/E ratio than BMY: RHHBY (26.78) vs BMY (17.16). RHHBY YTD gains are higher at: 44.916 vs. BMY (-5.422). RHHBY has higher annual earnings (EBITDA): 18B vs. BMY (15.1B). RHHBY has less debt than BMY: RHHBY (33B) vs BMY (50.9B). RHHBY has higher revenues than BMY: RHHBY (63.5B) vs BMY (47.7B).
BMYRHHBYBMY / RHHBY
Capitalization104B312B33%
EBITDA15.1B18B84%
Gain YTD-5.42244.916-12%
P/E Ratio17.1626.7864%
Revenue47.7B63.5B75%
Total CashN/A12B-
Total Debt50.9B33B154%
FUNDAMENTALS RATINGS
BMY vs RHHBY: Fundamental Ratings
BMY
RHHBY
OUTLOOK RATING
1..100
2475
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
3398
PRICE GROWTH RATING
1..100
5241
P/E GROWTH RATING
1..100
4814
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (5) in the Pharmaceuticals Major industry is in the same range as RHHBY (15) in the null industry. This means that BMY’s stock grew similarly to RHHBY’s over the last 12 months.

RHHBY's Profit vs Risk Rating (63) in the null industry is somewhat better than the same rating for BMY (100) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than BMY’s over the last 12 months.

BMY's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (98) in the null industry. This means that BMY’s stock grew somewhat faster than RHHBY’s over the last 12 months.

RHHBY's Price Growth Rating (41) in the null industry is in the same range as BMY (52) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to BMY’s over the last 12 months.

RHHBY's P/E Growth Rating (14) in the null industry is somewhat better than the same rating for BMY (48) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew somewhat faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYRHHBY
RSI
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
51%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
47%
MACD
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 9 days ago
52%
Bullish Trend 2 days ago
52%
Declines
ODDS (%)
Bearish Trend 21 days ago
54%
Bearish Trend 7 days ago
47%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
37%
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
BMY
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HLAL62.620.19
+0.30%
Wahed FTSE USA Shariah ETF
EDGH30.290.05
+0.16%
3EDGE Dynamic Hard Assets ETF
HSCZ38.740.05
+0.14%
iShares Currency Hdgd MSCI EAFE SmCp ETF
IIGD24.880.02
+0.10%
Invesco Investment Grade Defensive ETF
SPEM46.90-0.02
-0.04%
SPDR® Portfolio Emerging Markets ETF

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+5.62%
PFE - BMY
67%
Closely correlated
+1.67%
MRK - BMY
58%
Loosely correlated
+1.23%
ABBV - BMY
57%
Loosely correlated
+2.62%
AMGN - BMY
55%
Loosely correlated
+2.09%
BIIB - BMY
54%
Loosely correlated
+0.32%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
+0.45%
RHHVF - RHHBY
65%
Loosely correlated
+1.94%
NVS - RHHBY
37%
Loosely correlated
+1.09%
JNJ - RHHBY
37%
Loosely correlated
-0.04%
RHHBF - RHHBY
32%
Poorly correlated
-4.30%
BMY - RHHBY
28%
Poorly correlated
+5.62%
More